Washington University School of Medicine in St. Louis | Strategic Alliance Partners

Dr Thaker discusses the rationale for combining relacorilant with nab-paclitaxel in platinum-resistant ovarian cancer, and the future of the ROSELLA trial.

Premal Thaker, MD, MS, discusses the role of the glucocorticoid receptor pathway and the development of chemoresistance in ovarian cancer.

Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.

Domenica Lorusso, MD, PhD, and Premal Thaker, MD, highlight the upcoming phase 3 ROSELLA trial of relacorilant in platinum-resistant ovarian cancer.

Faculty at Washington University School of Medicine in St. Louis have designed a clinical trial development fellowship education program.

Neha Mehta-Shah, MD, MSCI, discusses unmet needs and future developments in the treatment of patients with peripheral T-cell lymphoma.

Andrew Davis, MD, discusses the use of antibody-drug conjugates in breast cancer, highlighting recent updates with these agents in the treatment paradigm.

Olivia Aranha, MD, PhD, discusses data supporting the use of HIPEC for patients with peritoneal carcinomatosis in gastrointestinal malignancies.

Michael Iglesia, MD, PhD, discusses the potential role of disease etiology in frontline HCC treatment decision-making.

Two clinical trials for AML or MDS are open and enrolling at Siteman Cancer Center and Washington University School of Medicine in St. Louis.

Michael Iglesia, MD, PhD, discusses uncertainties surrounding the selection of second-line treatment approaches in hepatocellular carcinoma.

Katrina S. Pedersen, MD, MS, discusses key updates in the therapeutic landscape for patients with molecularly targetable metastatic colorectal cancer.

Michael Iglesia, MD, PhD, discusses outcomes from the phase 3 COSMIC-312 trial of first-line cabozantinib plus atezolizumab in hepatocellular carcinoma.

Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer.

Premal Thaker, MD, MS, discusses the phase 3 RAMP-301 trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.

Katrina S. Pedersen, MD, MS, discusses the evolution of the role of immunotherapy in the treatment of patients with hepatocellular carcinoma.

Katrina S. Pedersen, MD, MS, discusses the evolving use of cytoreductive surgery for patients with peritoneal carcinomatosis.

Katrina S. Pedersen, MD, MS, shares updates in the treatment of gastrointestinal cancers, including biliary tract cancer and neuroendocrine tumors.

Katrina S. Pedersen, MD, MS, details how the treatment of patients with gastrointestinal malignancies is evolving and notes notable trials as well as approvals.

Katrina S. Pedersen, MD, MS, discusses key updates and FDA approvals from 2023 in metastatic colorectal cancer.

Drs Lunning and Mehta-Shah highlight challenges that arise when diagnosing patients with peripheral T-cell lymphoma and how molecular testing results influence induction and consolidation treatment approaches for patients with ALK-negative anaplastic large cell lymphoma.

Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.

Expert oncologist Ian Hagemann, MD, PhD, shares insight into the process of making a differential diagnosis of low-grade serous ovarian cancer in light of adjacent disease and available IHC testing.

As a result of the Affordable Care Act’s Medicaid expansion, positive trends are becoming apparent regarding mortality rates for patients with cancer living in the states that have adopted Medicaid expansion.

Amy W. Zhou, MD, discusses ongoing and planned trials that may enhance therapeutic options for patients with myelofibrosis and anemia that are currently taking place at the Washington University School of Medicine in St. Louis.

Amy W. Zhou, MD, discusses combination therapies with ruxolitinib that may contribute to the treatment paradigm for patients with myelofibrosis, highlighting the importance of continued research with phase 3 confirmatory trials for patients with this disease.

Brad S. Kahl, MD, discusses ongoing and planned investigations within the landscape of mantle cell lymphoma.

Amy W. Zhou, MD, discusses the investigation of ruxolitinib given in conjunction with novel or emerging agents such as pacritinib and momelotinib, highlighting these agents’ potential at contributing to the treatment paradigm in myelofibrosis.

Amy W. Zhou, MD, highlights the unique mechanism of action of the JAK1/2 and ACVR1 inhibitor momelotinib and the importance of ongoing investigations of JAK inhibitor combination therapies in myelofibrosis.

Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the treatment of patients with mantle cell lymphoma, expands on key ongoing trials investigating these agents in earlier settings and in different combinations, and expands on what the addition of pirtobrutinib to the treatment arsenal has meant for this population.